Women's Health Approved Deal Benchmarks (2026)
Median upfront of $2.4B with total deal values reaching $7.4B.
Median Upfront
$2.4B
Total Deal Value
$6.3B
Royalty Range
15.8%–27%
Territory Multiplier
1x
Understanding Women's Health Deal Benchmarks at Approved
Approved Women's Health licensing deals command a median upfront payment of $2.4B, with values ranging from $1.7B at the low end to $2.9B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the women's health therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $5.1B to $7.4B, with a median of $6.3B. Royalty rates for women's health assets at this stage typically fall between 15.8% and 27% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $1.7B | $2.4B | $2.9B |
| Total Deal Value | $5.1B | $6.3B | $7.4B |
| Royalty Rate | 15.8% | — | 27% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2022 | Myovant Sciences | Sumitomo Pharma | $3.0B | $3.0B | acquisition |
| 2022 | TherapeuticsMD | Mayne Pharma | $173M | $173M | acquisition |
| 2022 | Organon | Forendo Pharma | $75M | $900M | option |
| 2023 | ObsEva | XOMA/Kissei | $55M | $350M | licensing |
| 2023 | Dare Bioscience | Bayer | $20M | $300M | licensing |
| 2022 | Evofem Biosciences | N/A (standalone) | $0M | $80M | licensing |
| 2023 | Mayne Pharma | N/A (standalone) | $0M | $350M | licensing |
| 2024 | Biora Therapeutics | N/A (standalone) | $0M | $150M | licensing |
| 2024 | Femasys | N/A (standalone) | $0M | $60M | licensing |
| 2023 | Sage Therapeutics | Biogen | $875M | $1.5B | collaboration |
See All Comparable Deals
View 10 comparable Women's Health transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Women's Health deals?
How does Global territory affect Women's Health deal value?
What royalty rates are typical for Approved Women's Health licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$38M upfront
Women's Health · Preclinical · Global
$93M upfront
Women's Health · Phase 1 · Global
$326M upfront
Women's Health · Phase 2 · Global
$865M upfront
Women's Health · Phase 3 · Global
$2.1B upfront
Oncology · Approved · Global
$1.5B upfront
Neurology/CNS · Approved · Global
$3.4B upfront
Immunology · Approved · Global
$3.5B upfront
Metabolic/Obesity · Approved · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Women's Health Approved Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/womens-health-approved-deals-global
<a href="https://solidus.ambrosiaventures.co/data/womens-health-approved-deals-global">Women's Health Approved Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=womensHealth&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.